SOLARA Solara Active Pharma Sciences Q3 FY26 results (Oct–Dec 2025) and concall
Solara Active Pharma Sciences reported a challenging Q3 FY26, primarily due to significant headwinds in its legacy ibuprofen business, which impacted overall gross margins to 47%. Despite this, the non-ibuprofen growth API segment demonstrated strong profitability with 56% gross margins and 25% EBITDA. The company is actively evaluating strategic options for the ibuprofen business and aims to revive its mothballed Vizag plant for multipurpose API production, while also reducing debt by INR 146 crores and targeting sub INR 500 crores by May '26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 16.3%, net profit down 312.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 300 | 273 | 319 | 314 | 349 +16% |
| EBITDA | 58 | 45 | 57 | 35 | 37 −36% |
| Net profit | 8 | -2 | 11 | -10 | -17 −312% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
